ProPhase Labs (PRPH) Expected to Announce Quarterly Earnings on Monday

ProPhase Labs (NASDAQ:PRPH) is anticipated to release its Q1 2026 results before the market opens on Monday, May 18th. Analysts expect ProPhase Labs to post earnings of ($1.20) per share and revenue of $9.67 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 19, 2026 at 10:00 AM ET.

ProPhase Labs Stock Performance

PRPH opened at $0.12 on Monday. The stock has a market capitalization of $725,651.00, a price-to-earnings ratio of -0.03 and a beta of 0.15. The company has a fifty day moving average of $0.12 and a 200 day moving average of $0.89. ProPhase Labs has a fifty-two week low of $0.07 and a fifty-two week high of $6.66. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.14 and a current ratio of 0.14.

Hedge Funds Weigh In On ProPhase Labs

An institutional investor recently bought a new position in ProPhase Labs stock. XTX Topco Ltd bought a new stake in shares of ProPhase Labs, Inc. (NASDAQ:PRPH) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 102,506 shares of the company’s stock, valued at approximately $40,000. XTX Topco Ltd owned approximately 0.25% of ProPhase Labs as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.